tci.motf.store
Open in
urlscan Pro
2606:4700:3034::ac43:8eb0
Public Scan
URL:
https://tci.motf.store/
Submission: On January 21 via api from US — Scanned from US
Submission: On January 21 via api from US — Scanned from US
Form analysis 2 forms found in the DOM
GET https://www.iavi.org/
<form role="search" method="get" id="searchform" class="searchform" action="https://www.iavi.org/">
<div>
<label class="screen-reader-text" for="s">Search for:</label>
<input type="text" value="" name="s" id="s">
<input type="submit" id="searchsubmit" value="Search">
</div>
</form>Name: mc-embedded-subscribe-form — POST https://iavi.us7.list-manage.com/subscribe/post?u=65ad404c928bcb0edfd984a08&id=bfee2c6c82&f_id=00d0dce4f0
<form action="https://iavi.us7.list-manage.com/subscribe/post?u=65ad404c928bcb0edfd984a08&id=bfee2c6c82&f_id=00d0dce4f0" method="post" id="mc-embedded-subscribe-form" name="mc-embedded-subscribe-form" class="validate" target="_blank"
novalidate="novalidate">
<div id="mc_embed_signup_scroll">
<h2>Subscribe</h2>
<p>Use this form to receive updates on IAVI‘s work and the latest news from the field.</p>
<div class="mc-field-group">
<label for="mce-FNAME" class="mc-label-ghost">First Name</label>
<input type="text" name="FNAME" class="required text" required="" id="mce-FNAME" value="" placeholder="First Name *" aria-required="true">
</div>
<div class="mc-field-group">
<label for="mce-LNAME" class="mc-label-ghost">Last Name</label>
<input type="text" name="LNAME" class="required text" id="mce-LNAME" value="" required="" placeholder="Last Name *" aria-required="true">
</div>
<div class="mc-field-group"><label for="mce-EMAIL" class="mc-label-ghost">E-mail Address</label><input type="email" name="EMAIL" class="required email" id="mce-EMAIL" value="" required="" placeholder="E-mail Address *" aria-required="true"></div>
<div class="mc-field-group input-group">
<h2>Subscription Type </h2>
<ul>
<li><input type="checkbox" name="group[80579][1]" id="mce-group[80579]-80579-0" value=""><label for="mce-group[80579]-80579-0">IAVI Updates<span>Periodic updates on recent advances in biomedical innovations, policy initiatives, funding
updates, stories from the field, and IAVI’s Discovery Newsletter.</span></label></li>
<li><input type="checkbox" name="group[80579][2]" id="mce-group[80579]-80579-1" value=""><label for="mce-group[80579]-80579-1">IAVI Report<span>A publication covering the latest scientific and policy research in the quest to develop vaccines,
antibodies, and other biomedical innovations to combat the spread of HIV and other infectious diseases.</span></label></li>
</ul>
</div>
<div id="mce-responses" class="clear">
<div class="response" id="mce-error-response" style="display: none;"></div>
<div class="response" id="mce-success-response" style="display: none;"></div>
</div>
<div aria-hidden="true" style="position: absolute; left: -5000px;"><label for="hidden-mc-element">by Mailchimp</label><input type="text" name="b_65ad404c928bcb0edfd984a08_bfee2c6c82" id="hidden-mc-element" tabindex="-1" value=""></div>
<div class="clear"><input type="submit" name="subscribe" id="mc-embedded-subscribe" class="button button--primary" value="Subscribe"></div>
</div>
</form>Text Content
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store
and/or access device information. Consenting to these technologies will allow us
to process data such as browsing behavior or unique IDs on this site. Not
consenting or withdrawing consent, may adversely affect certain features and
functions.
Functional Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose
of enabling the use of a specific service explicitly requested by the subscriber
or user, or for the sole purpose of carrying out the transmission of a
communication over an electronic communications network.
Preferences Preferences
The technical storage or access is necessary for the legitimate purpose of
storing preferences that are not requested by the subscriber or user.
Statistics Statistics
The technical storage or access that is used exclusively for statistical
purposes. The technical storage or access that is used exclusively for anonymous
statistical purposes. Without a subpoena, voluntary compliance on the part of
your Internet Service Provider, or additional records from a third party,
information stored or retrieved for this purpose alone cannot usually be used to
identify you.
Marketing Marketing
The technical storage or access is required to create user profiles to send
advertising, or to track the user on a website or across several websites for
similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about
these purposes
Accept Deny View preferences Save preferences View preferences
Cookie Policy {title} {title}
IAVI Skip to content
Menu Close
Back to Main Menu
* Our Work
* Research & Development
* Discovery
* Epidemiology
* Clinical Development
* Product Development
* Global Access
* Advocacy & Community Engagement
* Health Areas
* Pipeline
* HIV Vaccines
* HIV Antibodies
* Tuberculosis
* Emerging Infectious Diseases
* About
* About IAVI
* About IAVI
* Our Story
* Careers
* Diversity, Equity, & Inclusion
* Financial Statements
* Regions
* Africa
* Europe
* India
* United States
* Leadership
* Board of Directors
* Senior Leadership
* Funders & Partners
* Funders
* Partnerships
* Media & Resources
* News & Press
* Features
* Press Releases
* In The News
* Digital Media
* Videos
* Podcasts
* Resources
* IAVI Report
* Scientific Publications
* Vaccine Literacy Library
* Fact Sheets & Publications
Search
Close
Search for:
* Quick Links
* Our Work
* Emerging Infectious Diseases
* Pipeline
* Senior Leadership
* Trending Now
* HIV Vaccines
* HIV Antibodies
* Tuberculosis
AFFORDABLE, ACCESSIBLE
VACCINES & ANTIBODIES
We are a nonprofit scientific research organization that develops vaccines and
antibodies for HIV, tuberculosis, and emerging infectious diseases.
About us
OUR APPROACH
--------------------------------------------------------------------------------
We take a full-circle approach to product development, from the grassroots level
to the lab to legislative bodies.
MISSION
--------------------------------------------------------------------------------
To translate scientific discoveries into affordable, globally accessible public
health solutions.
VISION
--------------------------------------------------------------------------------
A world where all people have equitable access to innovative vaccines and
therapeutics.
OUR HEALTH AREAS
* HIV
* Tuberculosis
* Lassa fever
* Marburg virus
* Sudan Ebolavirus
* COVID-19
HIV
THE CHALLENGE
HIV/AIDS remains one of the deadliest infectious diseases, with 1.3 million
people acquiring HIV in 2022. Given the complexities of HIV, traditional
approaches to vaccine development have so far failed to result in a vaccine that
provides protection against HIV. However, a vaccine is still needed to bring a
true end to the HIV pandemic. Source: UNAIDS
OUR SOLUTION
IAVI scientists and our collaborators are developing next-generation HIV
vaccines to address the challenges of HIV vaccine design. Together, we have
pioneered promising new vaccination strategies and the discovery of broadly
neutralizing antibodies (bnAbs) against HIV. IAVI and our partners are
developing HIV bnAbs to prevent HIV acquisition while we advance vaccine
candidates.
TUBERCULOSIS
THE CHALLENGE
Tuberculosis (TB) is the world’s leading infectious disease killer. In
2022, 10.6 million people fell ill with TB and 1.3 million people died of TB
disease. The only available TB vaccine is the century-old Bacille
Calmette-Guérin, or BCG. While this vaccine has efficacy in protecting against
severe TB disease in infants and young children, it is largely ineffective in
adolescents and adults, among whom most transmission and disease occurs. Source:
WHO
OUR SOLUTION
IAVI works across our global hubs with a diverse network of partners to advance
the most promising TB vaccine candidates from discovery through clinical trials,
and eventually, to post-licensure access. Our work extends to policy and
advocacy initiatives that support TB vaccine development and access in regions
where new vaccines are needed most.
LASSA FEVER
THE CHALLENGE
Lassa fever is an acute viral hemorrhagic illness endemic to West Africa which
causes significant annual outbreaks of disease. Lassa fever is difficult to
diagnose, and surveillance data is limited. Current estimates range from 300,000
to 500,000 cases and 5,000 related deaths each year. No licensed vaccines for
Lassa fever exist. Source: WHO
OUR SOLUTION
IAVI is developing a single-dose vaccine candidate for Lassa that is based on a
recombinant vesicular stomatitis virus (rVSV) vector. This technology is similar
to that underlying an approved Ebola Zaire virus vaccine. IAVI’s Lassa vaccine
candidate was well tolerated and immunogenic over a wide dose range in a Phase I
clinical study. IAVI also conducts Lassa epidemiological studies and modeling to
support future vaccine access.
MARBURG VIRUS
THE CHALLENGE
Marburg virus is a filovirus and the causative agent of Marburg virus disease
(MVD), which has a case fatality ratio of up to 88%. Marburg virus has the
capacity to cause outbreaks with high fatality rates and is a potential
bioterror threat. No vaccines or antiviral treatments are approved for MVD. A
Marburg vaccine is urgently needed to respond to future outbreaks. Source: WHO
OUR SOLUTION
IAVI is developing a vaccine candidate for Marburg that is based on a
recombinant vesicular stomatitis virus (rVSV) vector. This technology is similar
to that underlying an approved Ebola Zaire virus vaccine, which is now approved
by the U.S. FDA and registered for use in several African countries. Preclinical
data demonstrates that IAVI’s Marburg vaccine candidate is highly protective in
an animal model with one dose.
SUDAN EBOLAVIRUS
THE CHALLENGE
Sudan ebolavirus is a filovirus and causes outbreaks of Ebola disease, most
recently in 2022 in Uganda. Case fatality rates of Ebola disease caused by Sudan
ebolavirus have varied from 41% to 100% in past outbreaks. The licensed vaccine
for Ebola Zaire virus does not provide cross protection against the Sudan
strain. An Ebola Sudan vaccine is urgently needed to prevent and respond to
future outbreaks. Source: WHO
OUR SOLUTION
IAVI is developing a vaccine candidate for Sudan ebolavirus that is based on a
recombinant vesicular stomatitis virus (rVSV) vector similar to the technology
underlying an approved Ebola Zaire virus vaccine. During the 2022 Ebola outbreak
in Uganda, the WHO selected IAVI’s Sudan ebolavirus vaccine candidate for a
planned ring vaccination trial. While the trial did not go forward due to
outbreak control, IAVI has continued clinical development to prepare for future
outbreaks.
COVID-19
THE CHALLENGE
Since December 2019, over 760 million cases of COVID-19 and 6.9 million deaths
have been recorded worldwide, but the actual number is thought to be higher.
While highly effective, approved COVID-19 vaccines do not fully block
transmission or breakthrough infection. Additional COVID-19 vaccines continue to
be an urgent need, particularly vaccines suitable for widespread use in middle
and low-income countries. Source: WHO
OUR SOLUTION
IAVI is developing a COVID-19 vaccine candidate that is based on a recombinant
vesicular stomatitis virus (rVSV) vector. The vaccine candidate has demonstrated
safety in humans when administered intramuscularly and has been produced at
scale to support larger future clinical trials. IAVI is also investigating an
intranasal formulation of our COVID-19 vaccine candidate to prevent infection.
OUR IMPACT
--------------------------------------------------------------------------------
WE CONDUCT PRECLINICAL AND CLINICAL TRIALS OF OUR OWN VACCINES AND ANTIBODIES.
OUR FOCUS IS ON DISEASES OF GLOBAL IMPORTANCE FOR WHICH THERE IS NO MARKET AND
LITTLE FINANCIAL INCENTIVE FOR DEVELOPMENT. WE ALSO COLLABORATE WITH AND SUPPORT
OTHER SCIENTIFIC ORGANIZATIONS TO CONDUCT THEIR OWN CLINICAL TRIALS OF PRIORITY
DISEASE PREVENTION AND THERAPEUTIC INTERVENTIONS.
--------------------------------------------------------------------------------
255 partners from academic, biotech, pharma sectors, civil society, and global
health initiatives
--------------------------------------------------------------------------------
53 biologics candidates supported by the IAVI Product Development Center, out of
which 25 advanced to clinical trials
--------------------------------------------------------------------------------
70,000 volunteers enrolled in observational epidemiology studies
OUR LOCATIONS
--------------------------------------------------------------------------------
IAVI AFRICA
* Cape Town Office, South Africa
* Nairobi Office, Kenya
IAVI EUROPE
* Amsterdam Office, The Netherlands
* Human Immunology Lab, London, U.K.
IAVI INDIA
* Gurugram, Haryana Office
* Antibody Translational Research Program, IAVI-THSTI, Faridabad
IAVI U.S.
* New York Office
* Vaccine Design & Development Lab, New York
* Neutralizing Antibody Center, California
RECENT NEWS & MEDIA
Previous Next
Features
IAVI RECOMMENDS NEW BUSINESS MODELS FOR INCREASING ACCESS TO MONOCLONAL
ANTIBODIES
January, 04 2024
Together with partners Unitaid, the Medicines Patent Pool, and Wellcome, IAVI
has released a set of new recommendations for improving access to monoclonal
antibodies (mAbs) in low-income countries. Monoclonal antibodies are used today
to treat cancers, autoimmune disorders, and are currently being explored as a
new preventive and treatment tool for infectious diseases. Access to mAbs in
low-income country contexts is extremely limited, and new approaches are needed
to ensure access. Read more about the new business approaches that can advance
mAb access.
Read More
Features
DEVELOPMENT OF THE CANDIDATE TUBERCULOSIS VACCINE H56:IC31 ENDED BASED ON EARLY
DATA FROM THE PREVENTION OF RECURRENCE TB CONSORTIUM
December, 19 2023
The first analyses of data from the Phase IIb vaccine trial A-055 show that the
tuberculosis (TB) vaccine candidate, H56:IC31, was well tolerated and
demonstrated an immune response compared to the placebo in participants, all of
whom had previously had TB. However, the primary analysis showed it did not
provide protection against TB recurrence, reported Statens Serum Institut (SSI),
IAVI, and trial partners who are part of the Prevention of Recurrence (POR) TB
Consortium today. Based on these trial data, SSI has stopped development of the
vaccine. A supporting analysis points in the directi
Read More
Press Release
IAVI AND ZENDAL ANNOUNCE FUNDING FOR EFFICACY TRIAL OF PROMISING TB VACCINE
CANDIDATE IN AFRICA
December, 18 2023
TB kills 1.3 million people a year and sickens more than 10 million people
annually. A new TB vaccine is needed to reach the global End TB goals. MTBVAC is
a highly promising vaccine candidate that has the potential to be used as an
alternative to BCG vaccination in infants and for prevention of TB disease in
adolescents and adults. Grant from the Bill & Melinda Gates Foundation to IAVI
will support efficacy trial. Kabelo Mabeleng prepares Duglas Netshidzivhani for
a vaccine trial at the Aurum Institute Rustenberg, South Africa. Credit: Mwangi
Kirubi NEW YORK, U.S. and PORRIÑO, SPAIN
Read More
Features
MEET THE SCIENTIST PODCAST: AN INTERVIEW WITH JOYEETA MUKHERJEE, PH.D.,
ASSOCIATE DIRECTOR AT IAVI, ON THE INTERSECTION OF COMMUNITY AND SCIENCE
December, 06 2023
In this episode of Meet the Scientist, IAVI’s podcast series, we explore the
pivotal significance of community engagement in global collaborative research.
Tune in to discover how IAVI is highlighting the importance of community
partnership and engagement, an integral part of the product development process.
Joyeeta Mukherjee, Ph.D., associate director of access, research, and
development at IAVI in India, joins us to share insights into her work at the
intersection of community and science. Join the conversation as we delve into
the critical role of community engagement in global sci
Read More
Features
IAVI STATEMENT ON PREPVACC TRIAL
December, 06 2023
The PrEPVacc trial, an African-led, European-supported HIV prevention study
running in East and Southern Africa, has announced today at the International
Conference on AIDS and STIs in Africa that they will stop vaccinations due to
“little or no chance” of vaccine efficacy. The trial, which enrolled 1,512
participants, was designed to test whether two experimental HIV vaccine
combination regimens could protect against HIV; it also included a study arm
testing a new form of pre-exposure prophylaxis (PrEP) against the existing PrEP
standard. This arm of the trial will continue. IAVI pro
Read More
Features
THE MOMENT IS NOW: NAVIGATING THE PATH TO TB VACCINE SUCCESS AT THE UNION
CONFERENCE AND BEYOND
December, 06 2023
We joined thousands of researchers, advocates, and global health experts in
Paris in November for the first in-person Union World Conference on Lung Health
since 2019. This year’s Union Conference provided the first major in-person
gathering for the global TB community since the United Nations High Level
Meeting (HLM) on TB in September. With the commitments endorsed by member
states still fresh in our collective psyche, delegates were doubly focused on
what we must now do to translate member state commitments into action. The week
was also framed around the recently released WHO 2023 G
Read More
When women are given the opportunity to lead in science, they bring a unique
perspective that is invaluable to the field. This is not just a matter of
equality; it’s a matter of unleashing the full potential of science. Women
leaders in science bring a fresh perspective to the field that is essential for
driving innovation and progress.
Kawela Mumba-Mwangelwa
Graduate of IAVI’s Leadership Development Program, Co-principal Investigator at
the Center for Family Health Research in Zambia
We are a nonprofit scientific research organization that develops vaccines and
antibodies for HIV, tuberculosis, and emerging infectious diseases.
* Instagram
* YouTube
* Facebook
* LinkedIn
QUICK LINKS
--------------------------------------------------------------------------------
Careers
HIV Vaccines
HIV Antibodies
Tuberculosis
Emerging Infectious Diseases
CONTACT US
--------------------------------------------------------------------------------
IAVI U.S.
125 Broad Street, 9th Floor
New York, NY 10004
USAT: +1.212.847.1111
F: +1.212.847.1112
Contact us Diversity, Equity, & Inclusion Privacy Policy Terms of Use Compliance
& RFPs
©2024 International AIDS Vaccine Initiative. International AIDS Vaccine
Initiative®, IAVI®, and the IAVI logo® are registered trademarks of the
International AIDS Vaccine Initiative, Inc.
SUBSCRIBE
Use this form to receive updates on IAVI‘s work and the latest news from the
field.
First Name
Last Name
E-mail Address
SUBSCRIPTION TYPE
* IAVI UpdatesPeriodic updates on recent advances in biomedical innovations,
policy initiatives, funding updates, stories from the field, and IAVI’s
Discovery Newsletter.
* IAVI ReportA publication covering the latest scientific and policy research
in the quest to develop vaccines, antibodies, and other biomedical
innovations to combat the spread of HIV and other infectious diseases.
by Mailchimp
Manage consent